<DOC>
	<DOCNO>NCT01340183</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics drug AZD5099 intravenous administration single dose healthy volunteer . The result study form basis decision regard future development AZD5099 novel antibiotic treatment serious infection human .</brief_summary>
	<brief_title>Clinical Study Assessing Safety , Tolerability , Pharmacokinetics Intravenous AZD5099 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Provision sign date , write informed consent prior studyspecific procedure include genetic sampling Healthy male female ( nonchildbearing potential ) volunteer age 18 55 year ( inclusive ) suitable vein cannulation repeat venipuncture Females must negative pregnancy test screen admission unit , must lactate must nonchildbearing potential , confirm screen fulfil 1 follow criterion : Postmenopausal , define amenorrhea least 12 month follow cessation exogenous hormonal treatment follicle stimulate hormone ( FSH ) level within laboratorydefined postmenopausal range Documentation irreversible surgical sterilization hysterectomy , bilateral oophorectomy , bilateral salpingectomy tubal ligation Male volunteer willing use barrier contraception , ie , condom , day dose least 3 month dose investigational product Have body mass index ( BMI ) 18 30.5 kg/m2 weigh least 50 kg 100 kg inclusive History clinically important disease disorder , opinion Investigator , may either put volunteer risk participation study , influence result volunteer 's ability participate study History presence gastrointestinal , hepatic , renal disease condition know interfere absorption , distribution , metabolism , excretion drug Any clinically important illness , medical/surgical procedure , trauma within 4 week first administration investigational product History gastrointestinal ulcer disease , inflammatory bowel disease , indigestion symptom &gt; 3 time week , blood stool previous 6 month relate anal trauma For male volunteer history sexual dysfunction impotence judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Phase I</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>AZD5099</keyword>
	<keyword>volunteer</keyword>
	<keyword>safety drug AZD5099</keyword>
	<keyword>blood urine level AZD5099</keyword>
	<keyword>single intravenous dos</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>